Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies

Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies in Prostate Cancer Patients

Status

Terminated

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02971995

Acronym

PROSTEPIRM

Enrollment

Registered

2016-11-23

Start date

2014-12-01

Completion date

2016-10-01

Last updated

2026-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fluorocholine, Positron-Emission Tomography, Prostatic Neoplasm

Brief summary

Prostate cancer is the first cancer in humans (25%). The most widely used tracer in oncology, the 18-Fluoro DeoxyGlucose does not allow the study of prostatic neoplasia. On the other hand, Choline, which is an amino alcohol, is involved in the synthesis of cell membranes and has an affinity for prostate cells. Its concentration is directly proportional to cell proliferation. The analogue of choline has the advantage of having a rapid and stable accumulation over time in cancer cells, with a rapid urinary excretion (4 minutes after injection). The goal of this study is to assess the feasibility and the accuracy for targeting image guided prostate biopsy to detect prostate cancer after Imaging fusion of choline-PET/CT compared to 1.5T multiparametric magnetic resonance imaging (mpMRI) with 3D-transrectal ultrasound (TRUS) .

Interventions

DEVICEPET Scan ou TEP-TDM

Performance of the PET/CT using Flurocholine in order to detect the localization of the pathological fixation of the tracer and to determine the place where to take the biopsy

DEVICEmpMRI

Performance of the mpMRI in order to determine the place where to take the biopsy

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with suspicion of prostate cancer * Patients who performed prostate mpMRI and F-Choline 18 PET scan * Patient capable of receiving clear informations * Patient giving a written consent for their participation via a consent signed by both parents of the patient (or legal tutor) * Patient covered by a healthcare insurance

Exclusion criteria

* Patients without suspect image of neoplasia after mpMRI and F-Choline 18 PET scan

Design outcomes

Primary

Measure	Time frame
Number of image guided prostate biopsy in the zones detected by the TEP scan	at inclusion

Secondary

Measure	Time frame
Number of image guided prostate biopsy in the zones detected by the mpMRI	at inclusion

Contacts

PRINCIPAL_INVESTIGATORJean Louis Bonnal, MD

GHICL

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 13, 2026